1.	Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741
2.	AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: I173, CAN-NCIC-IND173, ZENECA-CAN-NCIC-IND173, CDR0000450844, IND173, NCT00265876
3.	AZD0530 in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2005-0977, P30CA016672, MDA-2005-0977, NCI-7569, CDR0000512970, 7565, NCT00397878
4.	AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000559142, U01CA062505, CCC-PHII-79, CHNMC-PHII-79, 7583, PHII-79, NCT00513071
5.	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00192, 06-074, CDR0000559632, N01CM62206, MSKCC-06074, 7584, NCT00513435
6.	Phase II Study of AZD0530 in Patients With Extensive Stage Small Cell Lung Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0621, N0621, NCT00528645
7.	Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00191, MSKCC-07112, CDR0000574281, N01CM62206, 07-112, 7567, NCT00559507
8.	Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8180C00034, NCT00558272
9.	Phase II Study of AZD0530 in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-052, PHL-052, 7552, NCT00607594
10.	Phase II Study of AZD0530 in Patients With Recurrent, Stage IIIB or IV Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Combination Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHLO-053, PHLO-053, 7555, NCT00638937
11.	AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8180C00015, AZD0530 Study 15, NCT00610714
12.	AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000588034, PMH-PHL-054, PHL-054, 7557, NCT00659360
13.	Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00193, N01CM62201, CDR0000594729, 16077A, UCCRC-16077A, 7597, NCT00669019
14.	AZD0530 in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 0805-02; IUCRO-0214, P30CA082709, IUMC-IUCRO-0214, IUCRO-0214, 8236, NCT00718809
15.	Phase II Randomized Study of Saracatinib in Patients With Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: UCCRC-10-436-B, 10-436-B, 8446, NCT01267266
16.	Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8480C00014, EuDract #2006-003505-55, NCT00475956
17.	Phase I Study in Patients With Solid Tumours Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8180C00023, AZD0530 study 23, NCT00496028
18.	AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8180C00021, NCT00704366